targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000014138 | MONDO_0018906 | NCT03105336 | Active, not recruiting | 2 | 2017-06-20 | null | null | null | null | Phase II+ | 1,606,317,770,278 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03105336 | Active, not recruiting | 2 | 2017-06-20 | null | null | null | null | Phase II+ | 1,606,317,770,278 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03321643 | Recruiting | 1 | 2018-03-07 | null | null | null | null | null | 1,666,447,310,878 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03321643 | Recruiting | 1 | 2018-03-07 | null | null | null | null | null | 1,666,447,310,878 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000014138 | MONDO_0018906 | NCT03321643 | Recruiting | 1 | 2018-03-07 | null | null | null | null | null | 1,666,447,310,878 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from11to20 | chembl | known_drug | 413,311 |
ENSG00000015520 | EFO_0000537 | NCT00738972 | Terminated | 3 | 2008-01-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 214,748,364,837 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 3 | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000015520 | EFO_0000537 | NCT00738972 | Terminated | 3 | 2008-01-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 214,748,364,837 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000015520 | EFO_0000537 | NCT00738972 | Terminated | 3 | 2008-01-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 214,748,364,837 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in some | Group enriched | none | chembl | known_drug | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | null | Detected in many | Tissue enhanced | from11to20 | slapenrich | affected_pathway | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | null | Detected in many | Tissue enhanced | from11to20 | chembl | known_drug | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | null | Detected in many | Tissue enhanced | from11to20 | expression_atlas | rna_expression | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 2 | null | Detected in many | Tissue enhanced | from11to20 | europepmc | literature | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | slapenrich | affected_pathway | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | chembl | known_drug | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | expression_atlas | rna_expression | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | europepmc | literature | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | slapenrich | affected_pathway | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | chembl | known_drug | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | expression_atlas | rna_expression | 413,311 |
ENSG00000017427 | MONDO_0007254 | NCT01446159 | Completed | 2 | 2011-06-13 | null | null | null | null | Phase II+ | 1,451,698,947,150 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | null | Detected in many | Tissue enhanced | from11to20 | europepmc | literature | 413,311 |
ENSG00000023228 | EFO_0003876 | NCT01799057 | Terminated | 4 | 2013-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 171,798,693,394 | The trial has been terminated due to difficulties with recruitment. | Phase 4 | 31/07/2013 | Terminated | 09/02/2016 | 31/12/2014 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 2 | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | EFO_0003876 | NCT01799057 | Terminated | 4 | 2013-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 171,798,693,394 | The trial has been terminated due to difficulties with recruitment. | Phase 4 | 31/07/2013 | Terminated | 09/02/2016 | 31/12/2014 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | EFO_0003876 | NCT01799057 | Terminated | 4 | 2013-07-01 | Terminated | stopped | Phase IV | Phase III+ | Phase II+ | 171,798,693,394 | The trial has been terminated due to difficulties with recruitment. | Phase 4 | 31/07/2013 | Terminated | 09/02/2016 | 31/12/2014 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | EFO_0003876 | NCT05132439 | Recruiting | 3 | 2022-03-01 | null | null | null | Phase III+ | Phase II+ | 1,065,151,890,457 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | 2 | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | EFO_0003876 | NCT05132439 | Recruiting | 3 | 2022-03-01 | null | null | null | Phase III+ | Phase II+ | 1,065,151,890,457 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | EFO_0003876 | NCT05132439 | Recruiting | 3 | 2022-03-01 | null | null | null | Phase III+ | Phase II+ | 1,065,151,890,457 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000319 | cardiovascular disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | MONDO_0002050 | NCT00834652 | Completed | 4 | 2007-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 274,877,908,552 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | 2 | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | MONDO_0002050 | NCT00834652 | Completed | 4 | 2007-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 274,877,908,552 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000023228 | MONDO_0002050 | NCT00834652 | Completed | 4 | 2007-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 274,877,908,552 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0000618 | nervous system disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | greaterThan20 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT01718327 | Completed | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 352,187,319,927 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT01718327 | Completed | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 352,187,319,927 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT01718327 | Completed | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 352,187,319,927 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT01718327 | Completed | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 352,187,319,927 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT01718327 | Completed | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 352,187,319,927 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT01718327 | Completed | 2 | 2011-09-01 | null | null | null | null | Phase II+ | 352,187,319,927 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04550624 | Recruiting | 2 | 2021-08-09 | null | null | null | null | Phase II+ | 506,806,140,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04550624 | Recruiting | 2 | 2021-08-09 | null | null | null | null | Phase II+ | 506,806,140,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04550624 | Recruiting | 2 | 2021-08-09 | null | null | null | null | Phase II+ | 506,806,140,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04550624 | Recruiting | 2 | 2021-08-09 | null | null | null | null | Phase II+ | 506,806,140,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04550624 | Recruiting | 2 | 2021-08-09 | null | null | null | null | Phase II+ | 506,806,140,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04550624 | Recruiting | 2 | 2021-08-09 | null | null | null | null | Phase II+ | 506,806,140,947 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04645160 | Recruiting | 1 | 2022-03-04 | null | null | null | null | null | 695,784,703,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04645160 | Recruiting | 1 | 2022-03-04 | null | null | null | null | null | 695,784,703,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04645160 | Recruiting | 1 | 2022-03-04 | null | null | null | null | null | 695,784,703,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04645160 | Recruiting | 1 | 2022-03-04 | null | null | null | null | null | 695,784,703,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04645160 | Recruiting | 1 | 2022-03-04 | null | null | null | null | null | 695,784,703,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04645160 | Recruiting | 1 | 2022-03-04 | null | null | null | null | null | 695,784,703,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04656249 | Completed | 2 | 2018-01-01 | null | null | null | null | Phase II+ | 343,597,383,839 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04656249 | Completed | 2 | 2018-01-01 | null | null | null | null | Phase II+ | 343,597,383,839 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04656249 | Completed | 2 | 2018-01-01 | null | null | null | null | Phase II+ | 343,597,383,839 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04656249 | Completed | 2 | 2018-01-01 | null | null | null | null | Phase II+ | 343,597,383,839 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04656249 | Completed | 2 | 2018-01-01 | null | null | null | null | Phase II+ | 343,597,383,839 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04656249 | Completed | 2 | 2018-01-01 | null | null | null | null | Phase II+ | 343,597,383,839 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03996408 | Recruiting | 1 | 2019-06-24 | null | null | null | null | null | 618,475,290,966 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03996408 | Recruiting | 1 | 2019-06-24 | null | null | null | null | null | 618,475,290,966 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03996408 | Recruiting | 1 | 2019-06-24 | null | null | null | null | null | 618,475,290,966 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03996408 | Recruiting | 1 | 2019-06-24 | null | null | null | null | null | 618,475,290,966 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03996408 | Recruiting | 1 | 2019-06-24 | null | null | null | null | null | 618,475,290,966 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03996408 | Recruiting | 1 | 2019-06-24 | null | null | null | null | null | 618,475,290,966 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03951597 | Active, not recruiting | 2 | 2019-05-10 | null | null | null | null | Phase II+ | 1,065,151,890,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03951597 | Active, not recruiting | 2 | 2019-05-10 | null | null | null | null | Phase II+ | 1,065,151,890,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03951597 | Active, not recruiting | 2 | 2019-05-10 | null | null | null | null | Phase II+ | 1,065,151,890,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03951597 | Active, not recruiting | 2 | 2019-05-10 | null | null | null | null | Phase II+ | 1,065,151,890,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03951597 | Active, not recruiting | 2 | 2019-05-10 | null | null | null | null | Phase II+ | 1,065,151,890,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT03951597 | Active, not recruiting | 2 | 2019-05-10 | null | null | null | null | Phase II+ | 1,065,151,890,601 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04361331 | Active, not recruiting | 2 | 2020-03-06 | null | null | null | null | Phase II+ | 1,194,000,909,481 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04361331 | Active, not recruiting | 2 | 2020-03-06 | null | null | null | null | Phase II+ | 1,194,000,909,481 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04361331 | Active, not recruiting | 2 | 2020-03-06 | null | null | null | null | Phase II+ | 1,194,000,909,481 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04361331 | Active, not recruiting | 2 | 2020-03-06 | null | null | null | null | Phase II+ | 1,194,000,909,481 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04361331 | Active, not recruiting | 2 | 2020-03-06 | null | null | null | null | Phase II+ | 1,194,000,909,481 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04361331 | Active, not recruiting | 2 | 2020-03-06 | null | null | null | null | Phase II+ | 1,194,000,909,481 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT02162914 | Active, not recruiting | 2 | 2014-03-14 | null | null | null | null | Phase II+ | 1,546,188,228,023 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT02162914 | Active, not recruiting | 2 | 2014-03-14 | null | null | null | null | Phase II+ | 1,546,188,228,023 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT02162914 | Active, not recruiting | 2 | 2014-03-14 | null | null | null | null | Phase II+ | 1,546,188,228,023 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT02162914 | Active, not recruiting | 2 | 2014-03-14 | null | null | null | null | Phase II+ | 1,546,188,228,023 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT02162914 | Active, not recruiting | 2 | 2014-03-14 | null | null | null | null | Phase II+ | 1,546,188,228,023 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT02162914 | Active, not recruiting | 2 | 2014-03-14 | null | null | null | null | Phase II+ | 1,546,188,228,023 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04527679 | Not yet recruiting | 2 | 2020-10-01 | null | null | null | null | Phase II+ | 1,640,677,507,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04527679 | Not yet recruiting | 2 | 2020-10-01 | null | null | null | null | Phase II+ | 1,640,677,507,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04527679 | Not yet recruiting | 2 | 2020-10-01 | null | null | null | null | Phase II+ | 1,640,677,507,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04527679 | Not yet recruiting | 2 | 2020-10-01 | null | null | null | null | Phase II+ | 1,640,677,507,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04527679 | Not yet recruiting | 2 | 2020-10-01 | null | null | null | null | Phase II+ | 1,640,677,507,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_0005221 | NCT04527679 | Not yet recruiting | 2 | 2020-10-01 | null | null | null | null | Phase II+ | 1,640,677,507,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000037280 | EFO_1000131 | NCT02782403 | Terminated | 1 | 2017-03-20 | Terminated | stopped | null | null | null | 412,316,861,909 | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies. | Phase 1 | 20/03/2017 | Terminated | 19/11/2020 | 11/11/2019 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_1000131 | NCT02782403 | Terminated | 1 | 2017-03-20 | Terminated | stopped | null | null | null | 412,316,861,909 | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies. | Phase 1 | 20/03/2017 | Terminated | 19/11/2020 | 11/11/2019 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | EFO_1000131 | NCT02782403 | Terminated | 1 | 2017-03-20 | Terminated | stopped | null | null | null | 412,316,861,909 | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies. | Phase 1 | 20/03/2017 | Terminated | 19/11/2020 | 11/11/2019 | Insufficient_Enrollment | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01434602 | Completed | 1 | 2012-10-02 | null | null | null | null | null | 721,554,506,623 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01434602 | Completed | 1 | 2012-10-02 | null | null | null | null | null | 721,554,506,623 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01434602 | Completed | 1 | 2012-10-02 | null | null | null | null | null | 721,554,506,623 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01434602 | Completed | 1 | 2012-10-02 | null | null | null | null | null | 721,554,506,623 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01434602 | Completed | 1 | 2012-10-02 | null | null | null | null | null | 721,554,506,623 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01434602 | Completed | 1 | 2012-10-02 | null | null | null | null | null | 721,554,506,623 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01817751 | Active, not recruiting | 2 | 2013-04-11 | null | null | null | null | Phase II+ | 128,849,018,975 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01817751 | Active, not recruiting | 2 | 2013-04-11 | null | null | null | null | Phase II+ | 128,849,018,975 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01817751 | Active, not recruiting | 2 | 2013-04-11 | null | null | null | null | Phase II+ | 128,849,018,975 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01817751 | Active, not recruiting | 2 | 2013-04-11 | null | null | null | null | Phase II+ | 128,849,018,975 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01817751 | Active, not recruiting | 2 | 2013-04-11 | null | null | null | null | Phase II+ | 128,849,018,975 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT01817751 | Active, not recruiting | 2 | 2013-04-11 | null | null | null | null | Phase II+ | 128,849,018,975 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT00923117 | Terminated | 2 | 2008-06-01 | Terminated | stopped | null | null | Phase II+ | 180,388,627,053 | The study was terminated based on results of an interim analysis for futility. | Phase 2 | 30/06/2008 | Terminated | 30/09/2015 | 30/06/2012 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT00923117 | Terminated | 2 | 2008-06-01 | Terminated | stopped | null | null | Phase II+ | 180,388,627,053 | The study was terminated based on results of an interim analysis for futility. | Phase 2 | 30/06/2008 | Terminated | 30/09/2015 | 30/06/2012 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |